ASCO: Developing effective combination therapies for leukemia
Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various types of leukemia. The investigators believe that the promising data about the use of these therapeutic regimens may lead to new standards of care and more leukemia treatment options. Results from the clinical trials were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting...
ASCO: Studies show advances in treatment and understanding of BRCA-associated and triple-negative breast cancer
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer...
Ovarian cancer analysis identifies potential treatment biomarkers
MD Anderson researchers have identified potential biomarkers for the response of high-grade serous ovarian cancers (HGSC) to surgical resection...
Triple-negative breast cancer clinical trial allies with community oncologists
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy works for about half of these patients. But there is a significant need for personalized options to improve outcomes for all patients.
Through the Breast Cancer Moon Shot®, MD Anderson is conducting an innovative clinical trial, called ARTEMIS, to develop personalized therapy approaches...
Heated post-surgical chemotherapy improves survival for stage IV stomach cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a type of cancer treatment in which surgeons apply heated chemotherapy...
Computer-assisted design technology complements navigation system in pioneering orthopaedic surgery
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...
Breast, ovarian cancer trials find targeted therapies provide benefit over chemotherapy
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
Triple combination therapy with nivolumab is feasible for AML, MDS patients
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...
Moon Shot confronts challenges of multiple cancers driven by HPV
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...
Study defines genetic pathway for hard-to-treat form of lymphoma
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...